It's not a simple question, and the answer is far more nuanced than a single spot on a diagram
Most are mild to moderate and often improve as the body adjusts to treatment
Member-Exclusive Pricing JumpstartMD members pay just $79/month
The Syt1 peptide forms a helical structure and binds to a shallow pocket on the surface of the nanobody
Additionally, a Phase 2 open-label extension study evaluates long-term safety and efficacy of zasocitinib in 183 participants aged 1876 with both UC and CD who demonstrated clinical or symptomatic response at week 52 of their parent trials, focusing on treatment-emergent AEs and clinically significant changes in vital signs, laboratory values, and ECG over 108 weeks of continued treatment, having started in May 2025 with completion expected in December 2029 (NCT06764615)
Al-Ansari N, Samuel SM, Bsselberg D